Madrigal Pharma (MDGL) Misses Q3 EPS by 44c
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Join SI Premium – FREE
Madrigal Pharma (NASDAQ: MDGL) reported Q3 EPS of ($5.34), $0.44 worse than the analyst estimate of ($4.90). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Goldman Sachs Double Upgrades Bradsaude SA (SAUD3:BZ) to Buy
- JPMorgan Upgrades YDUQS Participacoes SA (YDUQ3:BZ) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
